( ment of schizophreniaincluding maintai...)Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants,Health

ment of schizophrenia including maintaining stability in adults who had been symptomatically stable on other antipsychotic medications for periods of three months or longer and observed for relapse during a period of up to 26 weeks. Aripiprazole is also indicated for the treatment of acute manic and mixed episodes associated with Bipolar I Disorder, and for maintaining efficacy in adults with Bipolar I Disorder with a recent manic or mixed episode who had been stabilized and then maintained for at least six (6) weeks. Physicians who elect to use aripiprazole for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual. Aripiprazole Injection is indicated for the treatment of agitation in adults with schizophrenia or bipolar disorder, manic or mixed.

Initially approved in November 2002, over 10 million prescriptions have been written for aripiprazole in the U.S.(5)

Aripiprazole is available by prescription only. Aripiprazole is available in tablets, orally disintegrating tablets, oral solution, and injection for intramuscular use.

Patients should talk to their healthcare professional for more information about aripiprazole.

IMPORTANT SAFETY INFORMATION:

Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk (1.6 to 1.7 times) of death compared to placebo (4.5% vs 2.6%, respectively). Aripiprazole is not approved for the treatment of patients with dementia-related psychosis (see Boxed WARNING).

     - Neuroleptic malignant syndrome (NMS)-As with all antipsychotic

       medications, a rare and potentially fatal condition known as NMS has

       been reported with aripiprazole. NMS can cause hyperpyrexia, muscle

       rigidity, diaphoresis, tachycardia, irregular pulse or blood pressure,

       cardiac dysrhythmia, and altered mental status. If signs and symptoms

       appear, immediate discontinuation is recom
'"/>




Page: 1 2 3 4 5 6 7 8 
Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral
Anticoagulant, Presented Today at the XXIst Congress of the
International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial
Combination Therapy with Januvia (sitagliptin) and Metformin Led to
Improvement in Markers of Beta Cell Function in Patients with Type
2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational
Use of Januvia and Metformin as Initial Combination Therapy
Provided Significant Glucose Lowering Efficacy over 54 Weeks in
Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical
Improvement with Orencia (Abatacept) in Children with Juvenile
Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly
Improved Migraine Pain on Several Efficacy Measures in a Phase II
Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational
Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients
With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational
Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational
Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in
Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine
Extended Release, An Investigational Nonstimulant Medication Filed
for the Treatment of ADHD in Children and Adolescents